Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension

Hack-Lyoung Kim, Eun Mi Lee, Shin Young Ahn and 10 more

Clinical Hypertension · 2023 · Review · CC BY

doi:10.1186/s40885-023-00234-9

Abstract

Hypertension is the leading cause of death in human being, which shows high prevalence and associated complications that increase the mortality and morbidity. Controlling blood pressure (BP) is very important because it is well known that lowering high BP effectively improves patients' prognosis. This review aims to provide a focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. The importance of ambulatory BP and home BP monitoring was further emphasized not only for the diagnosis but also for treatment target. By adopting corresponding BPs, the updated guideline recommended out-of-office BP targets for both standard and intensive treatment. Based on the consensus on corresponding BPs and Systolic Blood Pressure Intervention Trial (SPRINT) revisit, the updated guidelines recommended target BP in high-risk patients below 130/80 mmHg and it applies to hypertensive patients with three or more additional cardiovascular risk factors, one or more risk factors with diabetes, or hypertensive patients with subclinical organ damages, coronary or vascular diseases, heart failure, chronic kidney disease with proteinuria, and cerebral lacunar infarction. Cerebral infarction and chronic kidney disease are also high-risk factors for cardiovascular disease. However, due to lack of evidence, the target BP was generally determined at < 140/90 mmHg in patients with those conditions as well as in the elderly. Updated contents regarding the management of hypertension in special situations are also discussed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Level of evidence and classes of recommendations

Table 1 shows the levels of evidence and classes of recommendations defined in these updated guidelines.

Blood pressure measurement

Accurate measurement of blood pressure (BP) is essential for the diagnosis, management, and risk stratification of hypertension. Measured BP varies according to the measurement environment, behavior of individuals, measurement protocol, device used for the measurement, and technical skill of observers. Therefore, the diagnosis of hypertension should be confirmed by repeat office BP (OBP) measurements with standardized methods at repeat office visits (Table 2). Also, out-of-office BP measurement with either ambulatory BP monitoring (ABPM), or home BP monitoring (HBPM) is recommended as a complementary strategy for the diagnosis of hypertension.

Office blood pressure measurement

Mercury sphygmomanometers are banned in Korea in terms of Minamata Convention for the environmental concern of mercury; thus, BP should be measured with a validated non-mercury sphygmomanometer (dabl, Dublin, Ireland; http://www.dableducational.org). They are divided into two types of devices according to measurement techniques: auscultatory (Korotkoff method) and oscillometric devices (automated electronic device). Among them, auscultatory devices include aneroids and hybrid sphygmomanometers. Aneroids (mechanical type with a dial) are commonly used in clinical practice, but they require regular calibration to ensure the accuracy of the devices. Hybrid sphygmomanometers replace the mercury column with an electronic pressure column (manual electronic auscultatory device). BP measurement techniques and reading skills of the scale of these devices are similar to those of mercury sphygmomanometers, but they reduce the impact of observer error because meniscus sign is negligible. In oscillometric devices, mean arterial BP is estimated to be cuff pressure when oscillation amplitude is maximal, and then systolic BP (SBP) and diastolic BP (DBP) are computed by proprietary algorithms that are known only to the manufacturer. Therefore, since different devices are not interchangeable, these devices should be validated separately according to an established protocol. These devices may be inaccurate in some populations including old ages, pregnant women, children, individuals with very large or thin arms, and patients with arrhythmias or stiffened arteries.

To obtain accurate BP reading, reliable upper-arm cuff devices and proper techniques should be used (Table 2). BP is measured siting in a chair with back support with the upper arm at the heart level 5 minutes after rest. A cuff placement below the heart level leads to an overestimation of BP. Cuff to fit arm size is selected. A cuff smaller than required overestimates BP. For auscultatory devices, inflatable bladder length which is 75 to 100% of the individual’s middle upper-arm circumference and width 37 to 50% of the arm circumference is used. In automated devices, cuff size is selected according to the device’s instructions. For auscultatory readings, deflate cuff pressure 2 mmHg per beat or second. Faster deflation can lead to an underestimation of SBP and overestimation of DBP. At least two measurements of BP are taken and the average of the readings is used. BP is measured in both arms at the initial visit. Interarm SBP difference of > 10 mmHg must be confirmed with repeated measurements and then the arm with the higher BP should be used at subsequent visits. Persistent interarm SBP difference of above 20 mmHg is considered the presence of arterial diseases such as coarctation of aorta or upper-extremity arterial obstruction. If upper-arm BP cannot be measured due to a malformation or an arterial stenosis, then it should be measured in the legs. If the pulses of the lower extremities are weak, BP should be measured in the legs to exclude the presence of peripheral arterial disease. There is no consensus on measuring BP in the legs. Ankle BP, rather than calf or thigh BP, is measured in a supine position using a validated automated device with the cuff placed around the ankle/lower calf because where the cuff generally causes less discomfort and is easier to fit. Auscultatory technique is not feasible in most subjects; thus, it is not recommended to measure BP in the legs. Triplicate BP readings and the average of readings are required in patients with arrhythmias (particularly atrial fibrillation) because of beat-to-beat changes in BP. Positional BP measurement is recommended in diabetes mellitus (DM), old ages, and suspected orthostatic hypotension. All the hypertensive patients undergo pulse palpation at rest to determine heart rate and search for arrhythmias such as atrial fibrillation.

Out-of-office blood pressure measurement

Since BP is influenced by many factors, including environment, emotion, and circadian changes, a single office BP measurement can lead to incorrect diagnosis and unnecessary treatment for hypertension. Therefore, repeated measurements of OBP as well as out-of-office BP measurements of ABPM and HBPM are needed for proper diagnosis and treatment of hypertension. Among out-of-office BP measurements, ABPM is first recommended because it provides more comprehensive information on BP such as BP phenotypes, circadian BP patterns, and BP variability. However, HBPM is often a more practical in usual environment for its ease to use. Out-of-office BP measurement provides better prognostic information than OBP measurement alone.

Ambulatory blood pressure monitoring

The main benefit of ABPM is to provide average BP readings of daytime, nighttime, and 24-hours that cannot be detect by OBP alone. Thus, ABPM provides information on BP phenotypes (WCH, MH, and sustained hypertension), circadian patterns (dipper, nondipper, reverse dipper, extreme dipper, and morning surge), and BP variability. Most of the ABPM devices are automated and programmable to measure BP by validated oscillometric devices. To obtain satisfactory ABPM data, nondominant upper arm with a proper cuff should be used. BP readings are obtained every 15 minutes to 30 minutes during the daytime and every 30 minutes to 60 minutes during the nighttime. Appropriate ABPM provides at least 20 awake and 7 asleep BP readings, of which 70% should be valid. When measuring ABPM, it is important to instruct individuals to keep usual daily activities and nighttime sleep and to avoid strenuous exercise. They are asked to keep the body, especially their arm, still during each BP measurement. It is also necessary to instruct them to write in a diary. The key indications for ABPM are summarized in Table 3. ABPM is indicated in clinical conditions such as (1) confirmation of hypertension, (2) detection of WCH, MH, and dipping patterns, (3) assessment of the BP variability, and (4) monitoring antihypertensive medication efficacy in treated individuals. ABPM thresholds for hypertension is ≥130/80 mmHg over 24 hours, ≥135/85 mmHg for the daytime average, and ≥ 120/70 mmHg for nighttime average (all equivalent to OBP ≥140/90 mmHg) (Table 4). Physiologically, BP decreases during sleep. If nocturnal BP decreases by 10 to 20% compared to daytime levels, it is called dipper hypertension. However, dipping status is poorly reproducible. ABPM provides more information on hypertension-mediated organ damage (HMOD) than OBP. If nocturnal BP has a less than 10% fall (nondipper), it is associated with high risk of left ventricular hypertrophy, myocardial ischemia, and death compared to dipper hypertension. Reverse dippers may also have autonomic dysfunction and be at high risk of hemorrhagic stroke and cardiovascular (CV) mortality. BP decrease of 20% or more (extreme dipper) may be associated with high risk for ischemic stroke and atherosclerosis. A morning surge is considered a risk factor for CV disease (CVD), particularly stroke. However, definition, reproducibility, and treatment of the morning surge should be answered.

Home blood pressure monitoring

HBPM has the main advantages of easy to use, relatively low cost, and long-term BP monitoring in treated individuals with hypertension. Thus, HBPM can be implanted during usual daily activities. However, BP measurement during HBPM is mostly unattended without medical supervision; thus, standardized protocol should be provided to all individuals for accurate readings (http://www.koreanhypertension.org/sense/family) (Table 5). Finger devices are not used due to inconsistent measurements. Wrist devices are generally not used due to their low accuracy when not positioned at the heart level; thus, validated wrist devices can be used in people with very large arms when upper-arm cuffs are not available. Automated upper-arm devices are currently validated and approved. BP is measured 5 minutes after rest in a sitting position. However, considering the efficiency of BP measurement, a shorter rest of 2 minutes may be an alternative to a rest of 5 minutes before BP measurement. A cuff to fit the arm is selected according to the device’s instructions, which is placed at the heart level. Accurate HBPM for accuracy is summarized in Table 5. HBPM is employed to confirm the diagnosis of hypertension, and to detect WCH, MH, and resistant hypertension. There is accumulating evidence that HBPM with or without telemonitoring may improve medication adherence in treated individuals with hypertension. In additions, HBPM is cost-effective in diagnosing and treating hypertension, and better predicts for HMOD and CV morbidity and mortality than OBP. However, HBPM is often inaccurate in arrhythmias, old ages, or pregnancy. Also, since HBPM gives little or no information on BP at work or during sleep, it does not help assess nocturnal hypertension, extreme BP decrease during sleep, and morning surge. Compared to OBP readings, HBPM values are usually lower; thus, HBPM threshold for diagnosing hypertension is ≥135/85 mmHg (equivalent to OBP ≥140/90 mmHg) in Table 4.

White coat hypertension and masked hypertension

According to results of OBP and out-of-office measurements, individuals are categorized into four phenotypes: (1) normotension (OBP and out-of-office BP not elevated), (2) WCH (elevated OBP [≥140/90 mmHg] but not elevated out-of-office BP [≤135/85 mmHg in awake BP and home BP or ≤ 130/80 mmHg in 24-hour mean BP]), (3) MH (elevated out-of-office BP but not OBP), and (4) sustained hypertension (both elevated OBP and out-of-office BP). Hypertension with WCE or white coat uncontrolled hypertension (WCUH) describes elevated OBP but not HBPM or ABPM in treated individuals. MUCH describes elevated out-of-office BP but not OBP in treated individuals.

White coat hypertension

Although different among studies, the prevalence of WCH is approximately 15 to 30% in the general population and hypertension with WCE or WCUH is 30 to 40% in treated individuals. According to the registry data on ABPM in secondary or tertiary centers supported by the Korean Society of Hypertension (Korean Ambulatory Blood Pressure Monitoring [Kor-ABP] Registry), WCH was estimated to be 14.9% of 1916 individuals who underwent ABPM for the diagnosis of hypertension and WCUH was 13.5% of all treated individuals. WCH occurs more frequently in female sex, old age, no smoking, pregnancy, low body mass index, and stage I hypertension but not in patients with HMOD. WCH confers lower short-term risk within 5 years but is associated with higher CV events and progress to sustained hypertension during long-term follow-up. Thus, patients with WCH believe that periodic BP monitoring can detect transition to sustained hypertension. WCUH does not predict CV morbidity and mortality; however, the clinical implication is that it might lead to uncontrolled or pseudoresistant hypertension. Thus, further assessment of BP by ABPM or HBPM should be considered before starting medication or dose escalation in suspected WCH or WCUH.

Masked hypertension

MH occurs approximately 9 to 30% in individuals with normal OBP and MUCH occurs approximately 30 to 60% of treated individuals. According to the Kor-ABP Registry data, MH was observed in 17.6% of individuals who underwent ABPM for the diagnosis of hypertension, and MUCH was also observed in 13.8% of patients taking antihypertensive medications and in 35.1% of individuals with controlled OBP. Young age, male sex, cigarette smoking, alcohol drinking, anxiety, job stress, higher level of physical activity, DM, chronic kidney disease (CKD), and obstructive sleep apnea are associated with MH. In Kor-ABP Registry data, when hypertension was defined by mean 24-hour BP ≥130/80 mmHg, MUCH is associated with high-normal OBP, underuse of antihypertensive drugs, dyslipidemia, prior stroke, and left ventricular hypertrophy. MH may progress to sustained hypertension and both MH and MUCH have been associated with HMOD. There are still limited data on the threshold or reproducibility of MH and MUCH diagnoses. However, in individuals with normal or high-normal BP, screening for MH or MUCH suing ABPM or HBPM may be considered if they were smokers or alcoholics, or have metabolic syndrome, target organ damage, DM, exercise induced hypertension, or high job stress.

Unattended automated office blood pressure measurement

Unattended automated OBP (AOBP) is measured three times at 1-minute intervals after 5-minute rest in a quiet environment without any medical staff using an automated device. However, the protocol for measurement frequency and interval, and rest duration is inconsistent among studies. Although AOBP may reduce WCE, MH can be detected using AOBP as usual OBP. The BP readings using unattended AOBP give lower than usual OBP values; thus, threshold for diagnosing hypertension is similar to awake ambulatory BP. However, patients with mean office SBP < 130 mmHg generally have lower OBP values than the corresponding awake ambulatory BP, regardless of their treatment status.

Blood pressure measurement using cuffless wearable devices

Several novel cuffless wearable mobile devices, such as smartwatches or smartphones, are used for BP measurement. They have sensors, which evaluate the pulsation of arterioles and estimate BP based on pulse wave velocity or other technologies. Recently, BP measurement using a photoplethysmography-based smartphone algorithm paired with a smartwatch is approved as a medical device, fulfilling International Organization for Standardization (ISO) standards. These devices have great benefits because they can easily and conveniently obtain multiple or even continuous BP measurements for days or weeks and there is no cuff-induced measurement error. However, they have two critical limitations that accuracy of sensor-based BP measurement and the reliability of wrist BP devices are low. BP values differ according to measurement methods; thus, they are presented as BP ranges rather than actual BP values. Future clinical practice requires device validation with an established protocol, BP measurement with standardization, education of BP measurement, and regular calibration with a reference device.

Central blood pressure measurement

Approximately 80% of brachial arterial pressure may be attributed to central arterial pressure. In addition, central BP has been reported to more closely correlate with target organ damage or prognosis. Although central BP might be useful for patients with significant differences between central and brachial artery pressures, it is not superior to conventional brachial BP in the treatment of hypertension.

Hypertension screening

Because it is well known that the higher the BP, the higher the risk of CVD and death, regular screening tests are strongly recommended to determine the presence of hypertension in all adults, except those who have already been diagnosed with hypertension. Available evidence on optimal screening intervals for the detection of hypertension remains limited.

However, many observational studies have shown that the earlier the hypertension is detected and treated, the lower the risk of CVD, which is indirect evidence for the benefit of early diagnosis of hypertension through screening in adults. In a randomized clinical trial of elderly community people in Canada, hospitalizations for CVD within 1 year were reduced by 9% in the group that received pharmacy-based hypertension screening and risk assessment compared to the group that did not. Previous studies have reported neither serious side effects or increased risk of disease associated with screening for hypertension, nor its negative effects on quality of life or psychological status. Although ABPM can cause minor side effects, such as sleep disturbance, pain/anxiety, bruising, and skin irritation, it may not be problematic because primary screening for hypertension is based on OBP. There is insufficient evidence on the optimal frequency of screening for hypertension in adults. BP measurement does not have serious side effects and the cost is not high, in many countries, the hypertension screening cycle is determined by considering the medical environment or health examination infrastructure level of their own countries rather than the result of cost-effectiveness analysis. The Korean Society of Hypertension suggests regular OBP measurement based on health checkups by the National Health Insurance Service in Korea. All adults who are over 20 years old are recommended for OBP measurements at least every 2 years. In adults aged ≥40 years, with a family history of hypertension, high-normal OBP (130–139/80–89 mmHg), or obesity, OBP measurement are indicated at least annually because of the high rate of progression of hypertension (Fig. 1).

Corresponding blood pressure

It is recommended to apply the same corresponding BP to the diagnosis and treatment of hypertension (Table 6). It is very similar to the 2017 American guidelines provided so that the concern of WCE and overtreatment needs to be balanced with the risk of mask effect and undertreatment during intensive BP control targeting BP below 130/80 mmHg.

Laboratory examination

Laboratory examinations are performed to identify additional CV risk factors, secondary causes of hypertension, subclinical organ damage, and concomitant diseases. Routine laboratory tests are mandatory before antihypertensive treatment. Other recommended and extended tests can be performed if necessary (Table 7). In the 12-lead electrocardiogram, the findings of left ventricular hypertrophy, left bundle branch block, and myocardial infarction are regarded as high risk for CVD. Proteinuria or hematuria suggests CKD, and glycosuria suggests DM. Blood hemoglobin and hematocrit levels can determine anemia. An increase in the volume of red blood cells is related to an increase in BP, but its correlation coefficient is very low. If hypokalemia is observed in the baseline evaluation, it suggests excessive state of inorganic corticoids such as primary aldosteronism as a cause of hypertension. In addition, baseline potassium levels should be evaluated because thiazide or loop diuretics can lose serum potassium. Hypokalemia is associated with increased lethargy, arrhythmias, and the incidence of DM and hyperkalemia can be caused by impaired renal function. An increase in serum creatinine level or a decrease in the estimated glomerular filtration rate (eGFR; < 60 mL/min/1.73m2) indicates a decrease in kidney function. When eGFR based on serum creatinine is inaccurate, it is recommended to measure serum cystatin C and eGFR using cystatin C in combination with serum creatinine. The serum concentration of cystatin C is not associated with sex, age, or muscle mass. Therefore, cystatin C is useful for the diagnosis of renal impairment in young men with high muscle mass and elderly women with low muscle mass. An increase in uric acid level is observed in gout, impaired renal function, obesity, or diuretic use. Fasting blood glucose and lipid tests are necessary for confirming hyperglycemia and dyslipidemia, respectively. In addition, when diuretics or β-blockers have long been used, the incidence of hyperglycemia and dyslipidemia increases, which can be evaluated by routine tests. Thyroid stimulating hormone is a useful indicator to confirm hypothyroidism and hyperthyroidism. An increase in cardiac to thoracic ratio on chest X-ray or pulmonary congestion/edema suggests heart failure. Calcification of the aortic arch represents arteriosclerosis. Proteinuria can be evaluated using a urine reagent strip, urine protein to creatinine ratio, or urine albumin to creatinine ratio (ACR). Considering the sensitivity and accuracy of the tests, the urine ACR is recommended. The first morning urine specimen is preferred for the detection of albuminuria. However, a random urine sample is acceptable if no first morning urine specimen is available. Albuminuria can be transiently observed in several pathologic and physiologic conditions such as, urinary tract infection, excessive exercise, taking nonsteroidal anti-inflammatory drugs, and menstrual blood in women. Albuminuria is defined as a urine ACR ≥30 mg/g (≥3 mg/mmol), and can be confirmed when the urine ACR > 300 mg/g (> 30 mg/mmol). If a urine ACR ≥30 mg/g (≥3 mg/mmol) is detected on no less than two occasions over at least 3 months, persistent albuminuria as a marker of kidney damage is present. It is recommended that routine laboratory tests should be evaluated at the first visit and annually. If the degree of hypertension is severe or if the hypertension is not well controlled even with standardized drug treatment, additional tests can be performed to evaluate asymptomatic organ damage or if clinically necessary. Transthoracic echocardiography is useful for diagnosing left ventricular hypertrophy. The measurement of carotid intima-media thickness is not recommended because it is not standardized and the clinical evidence is weak. Identification of carotid atherosclerotic plaques can be helpful in predicting prognosis.

Cardiovascular risk and treatment plan

The CV risk and treatment strategy for hypertension is shown in Table 8. Antihypertensive medication is generally not recommended for patients with prehypertension due to limited evidence. Patients with stage 1 hypertension with low CV risk need antihypertensive medications according to their BP status after lifestyle modification. Intermediate-risk and high-risk patients with stage 1 hypertension require immediate antihypertensive medications. Because most randomized clinical trials and meta-analyses show that antihypertensive medications are effective in reducing CV risk, antihypertensive medications along with lifestyle modification is recommended in stage 2 hypertension.

Target blood pressure

In general, the target SBP is < 140 mmHg and target DBP is < 90 mmHg unless in clinical conditions shown in Table 9. It is reasonable to reduce BP below 130/80 mmHg in individuals with CVD or high CV risk. On the other hand, it is recommended to control BP to less than 140/90 mmHg in low-risk and intermediate-risk groups. Clinical algorithms for reaching target BP are shown in Fig. 2. The main rationale of changing target BPs from around 130/80 mmHg to below 130/80 mmHg in high-risk patients is the adoption of corresponding BPs, which emphasize the balanced awareness of both WCE and masked effects during intensive BP control. Some studies for corresponding BPs using AOBP also support the idea that too much concern about WCE may result in undertreatment within the intensive target BP range. According to these corresponding BPs, achieved daytime ambulatory SBP in the intensive arm in Systolic Blood Pressure Intervention Trial (SPRINT), i.e., 126 mmHg could be equivalently applied to conventional OBP during which OBP is complemented by HBPM.

Antiplatelet therapy

It is clear that antiplatelet therapy can be used for secondary prevention after the onset of CVD in hypertensive patients. However, the study results are inconsistent in terms of the effect of antiplatelet therapy in the primary prevention of CVD. Although some guidelines recommended not using aspirin for primary prevention, use of low-dose aspirin still is beneficial for primary prevention in some patients with high-risk profiles. To reduce CV risk, antiplatelet agents, such as low-dose aspirin (100 mg), can be used to hypertensive individuals aged 40 to 70 years with high CV risk. It is a general recommendation in most practice guidelines to discourage the use of aspirin for primary prevention in the older patients, patients at high bleeding risk and patients low or intermediate CV risk. Antiplatelet agents are administered after BP is controlled, while bleeding complications are frequently checked.

Antidyslipidemic therapy

Lipid-lowering drug therapy is effective in preventing CVD in high-risk hypertensive patients. In hypertensive patients without CVD, statin was used to lower the LDL-cholesterol level by > 50%, when LDL-cholesterol was ≥130 mg/dL, and its CVD prevention effect is evident. It is recommended to lower LDL-cholesterol to less than 70 mg/dL in hypertensive patients with CVD.

Blood glucose control

The goal of glycemic control in diabetic patients is less than 6.5% of glycated hemoglobin. The glycated hemoglobin target may be lowered either if disease duration of diabetes is shorter or if there are no accompanying complications and low risk of hypoglycemia. However, glycemic control goals can be individualized in patients with severe hypoglycemia, short life expectancy, advanced microvascular and macrovascular complications, and the risk of developing hypoglycemia in the elderly aged 75 years or older. Since sodium glucose cotransporter-2 (SGLT-2) inhibitors not only lower BP, but also reduces the occurrence of CVD and slows the deterioration of kidney function, use of these drugs should be considered in hypertensive patients with diabetes. When used together with loop diuretics, caution should be paid because as excessive loss of body fluid may occur due to increased urine output.

Patient monitoring and follow-up

When starting a new antihypertensive drug or adjusting its dosage or dosing time, it is recommended to follow-up at least monthly until the target BP is reached to check the adherence to the drug and whether the BP is controlled. Stage II or more severe hypertension may be followed up more frequently. Electrolyte and kidney function tests are performed at least one to two times a year. If the target BP is reached and remains stable, patients are followed up every 3 to 6 months. Check whether patients’ adherence to drug therapy decreases with increasing follow-up intervals. Care should be taken to avoid missing blood tests. Encouragement to measure home BP can help determine BP control when follow-up intervals are extended.

Adherence

Reducing the number of dosing increases patient’s adherence, so once-daily antihypertensive dosing is recommended unless there is a special reason. In patients who are stably being taking the same drug and dosage during a long period of time, the administration of fixed-dose combination drug is considered because it has better adherence than combination therapy of free drugs. About half of hypertensive patients have dyslipidemia, so the number of patients taking both antihypertensive medications and statins is increasing. The use of the fixed- dose combination of antihypertensive drugs (especially calcium channel blockers and angiotensin receptor blocker [ARB]) and statins also improves patient adherence compared to free combination.

Diabetes mellitus

Evidence for the drug treatment of prehypertension in diabetic patients is still limited. In diabetic patients, lowering BP below 130/80 mmHg did not prove a preventive effect on CVD. Rather, lowering BP to < 130/80 mmHg worsened renal function in diabetic patients. Therefore, a general target BP of less than 140/90 mmHg is recommended for hypertensive patients with DM. However, in diabetic patients with high-risk clinical features including CV risk factors ≥1, CVD, stages 3, 4, or 5 CKD, and subclinical organ damage, it is considered to control BP below 130/80 mmHg.

Among oral antidiabetic drugs, SGLT-2 inhibitors have an antihypertensive effect. Thus, it may be necessary to adjust the dosage of antihypertensive drugs when used with SGLT-2 inhibitors.

Hypertension in the elderly

Although results of SPRINT and the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial have shown that intensive BP-lowering therapy is effective in elderly hypertensive patients, additional research is needed on target BP in adults at very old age, the frail elderly, and the elderly in a facility.

Orthostatic BP should be periodically measured to check for orthostatic hypotension. Since intensive BP control rather reduces the risk of orthostatic hypotension, there is no need to reduce the drug if orthostatic hypotension is suspected. Treatment of orthostatic hypotension includes nondrug treatment such as water/salt intake, cross-legged and squatting postures, use of compression stockings, and treatment with drugs such as midodrine, pyridostigmine and fludrocortisone.

Coronary artery disease

Considering the “J curve” phenomenon in hypertensive patients with CAD, an excessive decrease in SBP increases CV risk, which is more pronounced in patients with left ventricular hypertrophy. Therefore, hypertensive patients with CAD should be carefully managed so as not to lower SBP to less than 110 mmHg and DBP to less than 70 mmHg.

As antihypertensive medication, β-blockers should be considered first for 1 day to 1 month after acute myocardial infarction. ACE inhibitors are also effective in patients with acute myocardial infarction. In hypertensive patients with CAD, β-blockers, ACE inhibitors, or ARBs are recommended as first-line drugs. When symptom or BP control is not sufficient with these drugs, calcium channel blockers, diuretics, and aldosterone antagonists are recommended.

Atrial fibrillation

If hypertensive patients have atrial fibrillation, the risk of thromboembolism is high, so anticoagulation is considered unless contraindicated.

Aortic disease

Coarctation of aorta is usually corrected with surgical treatment in childhood. However, even after surgical correction, hypertension can be developed in childhood, requiring long-term follow-up. In some patients, coarctation of aorta is not found until adulthood, which progresses to severe hypertension, resulting in cardiac hypertrophy, left ventricular hypertrophy, and target organ damage accompanied by extensive collateral circulation down the coarctation site. However, there is still randomized study on an appropriate BP treatment strategy in patients with coarctation of aorta.

Bicuspid aortic valve is common in men and related to coarctation of aorta. Also, patients with bicuspid aortic valve are more likely to develop aortic disease than the general population. If BP is not controlled, it can progress to aortic aneurysm, leading to dangerous consequences such as aortic rupture. Therefore, it may be helpful to control BP to be below 130/80 mmHg in patients with bicuspid aortic valve. ARBs can be used when BP control is required in patients with severe aortic stenosis.

Chronic kidney disease

The main aim of controlling BP in patients with CKD is to slow the deterioration of renal function and reduce the morbidity and mortality of CVD. The SPRINT study has shown benefits in all-cause mortality and cardiovascular morbidity with a target SBP of < 120 mmHg in the hypertensive CKD subgroup without diabetes. However, the evidence for the benefit of a target SBP of less than 120 mmHg is less convincing in CKD at age < 50 years, diabetes, advanced CKD stage (eGFR < 20 mL/min/1.73m2), proteinuria > 1 g/day, and polycystic kidney disease. The updated Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Guideline for the management of BP in CKD patients who have not receive dialysis is based on the results of the SPRINT study, which used a standardized OBP measurement as a principle method. Because of difficulties in using a standardized OBP measurement in clinical practice, there are limitations in applying the updated target BP for CKD patients.

In randomized controlled trials and a large network meta-analysis, combination therapy was compared to monotherapy. Despite lowering proteinuria in the short term, combination therapy did not reduce all-cause mortality or cardiovascular morbidity. Also, it did not slow the progression of CKD to end-stage renal disease; however, combination therapy increased the incidence of acute renal injury and hyperkalemia compared to monotherapy. These results were similar in combination therapy with ARBs and direct renin inhibitors.

Erectile dysfunction

The relationship of hypertension and antihypertensive drugs with sexual dysfunction in women is not so clear as in men. According to the SPRINT study, hypertension and use of antihypertensive drugs were not associated with sexual dysfunction in middle-aged and elderly women.

In order to increase adherence to antihypertensive medications, all hypertensive patients should be regularly checked for sexual dysfunction during the follow-up period as well as at the early stage of diagnosis. In particular, for men complaining of sexual dysfunction, it is recommended to avoid prescription of β-blockers or diuretics, which are relatively related to sexual dysfunction, or to substitute other drugs for them.

Pregnancy

Hydralazine, methyldopa, labetalol, and nifedipine are useful oral antihypertensive drugs during pregnancy. However, methyldopa is not available in Korea. In emergency situations such as preeclampsia, intravenous labetalol is recommended; however, intravenous nitroprusside or nitroglycerin and oral nifedipine can also be used.

Cognitive impairment

Although previous studies have not shown a statistically significant preventive effect due to problems such as lack of power and short follow-up duration, it has been found that active BP-lowering treatment tends to reduce the incidence of dementia.

References 186

  1. 1.

    Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J Hypertens. 2017;35:421-441.

    Not in our library10.1097/hjh.0000000000001197

  2. 2.

    Stergiou GS, Palatini P, Parati G, O’Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39:1293-1302.

    Not in our library10.1097/hjh.0000000000002843

  3. 3.

    National Institute for Health and Care Excellence (NICE). Hypertension: management of hypertension in adults in primary care. 2006.

    Not in our library

  4. 4.

    Scientific Committee on Emerging and Newly Identified Health Risks. Mercury sphygmomanometers in healthcare and the feasibility of alternatives. 2009.

    Not in our library

  5. 5.

    Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379:905-914.

    Not in our library10.1016/s0140-6736(11)61710-8

  6. 6.

    Sheppard JP, Lacy P, Lewis PS, Martin U. Blood Pressure Measurement Working Party of the British and Irish Hypertension Society. Measurement of blood pressure in the leg: a statement on behalf of the British and Irish Hypertension Society. J Hum Hypertens. 2020;34:418-419.

    Not in our library10.1038/s41371-020-0325-5

  7. 7.

    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.

    Not in our library10.1161/01.hyp.0000107251.49515.c2

  8. 8.

    Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation?: a systematic review. J Fam Pract. 2006;55:130-134.

    Not in our library

  9. 9.

    Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-692.

    Not in our library10.1016/j.amjcard.2011.10.025

  10. 10.

    Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.

    Not in our library10.1056/nejmra060433

  11. 11.

    O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-1768.

    Not in our library10.1097/hjh.0b013e328363e964

  12. 12.

    Kario K, Shin J, Chen CH, Buranakitjaroen P, Chia YC, Divinagracia R, et al. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE Asia network. J Clin Hypertens (Greenwich). 2019;21:1250-1283.

    Not in our library10.1111/jch.13652

  13. 13.

    Stergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. Am J Hypertens. 2011;24:123-134.

    Not in our library10.1038/ajh.2010.194

  14. 14.

    Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018;138:e426-e483.

    Not in our library10.1161/cir.0000000000000597

  15. 15.

    Park S, Buranakitjaroen P, Chen CH, Chia YC, Divinagracia R, Hoshide S, et al. Expert panel consensus recommendations for home blood pressure monitoring in Asia: the Hope Asia network. J Hum Hypertens. 2018;32:249-258.

    Not in our library10.1038/s41371-017-0025-y

  16. 16.

    Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.

    Not in our library10.1001/jama.282.6.539

  17. 17.

    Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161.

    Not in our library10.1161/01.hyp.0000170138.56903.7a

  18. 18.

    Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 1998;16:971-975.

    Not in our library10.1097/00004872-199816070-00010

  19. 19.

    Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-home study. Hypertension. 2010;55:1346-1351.

    Not in our library10.1161/hypertensionaha.109.149336

  20. 20.

    Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-515.

    Not in our library10.1016/j.jacc.2005.03.070

  21. 21.

    Pierdomenico SD, Pierdomenico AM, Coccina F, Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of masked uncontrolled hypertension. Hypertension. 2018;72:862-869.

    Not in our library10.1161/hypertensionaha.118.11499

  22. 22.

    Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, et al. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study: Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens. 1998;16:733-738.

    Not in our library10.1097/00004872-199816060-00003

  23. 23.

    Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990;81:528-536.

    Not in our library10.1161/01.cir.81.2.528

  24. 24.

    Pierdomenico SD, Bucci A, Costantini F, Lapenna D, Cuccurullo F, Mezzetti A. Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease. J Am Coll Cardiol. 1998;31:1627-1634.

    Not in our library10.1016/s0735-1097(98)00163-6

  25. 25.

    Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183-2189.

    Not in our library10.1097/00004872-200211000-00017

  26. 26.

    Milazzo V, Di Stefano C, Vallelonga F, Sobrero G, Zibetti M, Romagnolo A, et al. Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. Parkinsonism Relat Disord. 2018;56:82-87.

    Not in our library10.1016/j.parkreldis.2018.06.032

  27. 27.

    Hamada T, Murata T, Narita K, Takahashi T, Wada Y, Kimura H, et al. The clinical significance of abnormal diurnal blood pressure variation in healthy late middle-aged and older adults. Blood Press. 2008;17:134-140.

    Not in our library10.1080/08037050802162839

  28. 28.

    Kim BK, Kim YM, Lee Y, Lim YH, Shin J. A reverse dipping pattern predicts cardiovascular mortality in a clinical cohort. J Korean Med Sci. 2013;28:1468-1473.

    Not in our library10.3346/jkms.2013.28.10.1468

  29. 29.

    Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401-1406.

    Not in our library10.1161/01.cir.0000056521.67546.aa

  30. 30.

    Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56:765-773.

    Not in our library10.1161/hypertensionaha.110.157149

  31. 31.
    Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis · 2017
    No notice
  32. 32.

    Brady TM, Charleston J, Ishigami J, Miller ER, Matsushita K, Appel LJ. Effects of different rest period durations prior to blood pressure measurement: the best rest trial. Hypertension. 2021;78:1511-1519.

    Not in our library10.1161/hypertensionaha.121.17496

  33. 33.

    Verberk WJ, Kroon AA, Lenders JW, Kessels AG, van Montfrans GA, Smit AJ, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension. 2007;50:1019-1025.

    Not in our library10.1161/hypertensionaha.107.094193

  34. 34.

    Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29-38.

    Not in our library10.1161/hypertensionaha.110.160911

  35. 35.
    Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial · 2018
    No notice
  36. 36.

    Arrieta A, Woods JR, Qiao N, Jay SJ. Cost-benefit analysis of home blood pressure monitoring in hypertension diagnosis and treatment: an insurer perspective. Hypertension. 2014;64:891-896.

    Not in our library10.1161/hypertensionaha.114.03780

  37. 37.

    The Korean Society of Hypertension. Guidelines for home blood pressure management. 2011.

    Not in our library

  38. 38.

    Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-232.

    Not in our library10.1161/hypertensionaha.109.129882

  39. 39.

    Faria J, Mesquita Bastos J, Bertoquini S, Silva J, Polónia J. Long-term risk of progression to sustained hypertension in white-coat hypertension with normal night-time blood pressure values. Int J Hypertens. 2020;2020:8817544.

    Not in our library10.1155/2020/8817544

  40. 40.

    Banegas JR, Segura J, Sobrino J, Rodríguez-Artalejo F, de la Sierra A, de la Cruz JJ, et al. Effectiveness of blood pressure control outside the medical setting. Hypertension. 2007;49:62-68.

    Not in our library10.1161/01.hyp.0000250557.63490.55

  41. 41.

    de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.

    Not in our library10.1161/hypertensionaha.110.168948

  42. 42.

    Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988;259:225-228.

    Not in our library10.1001/jama.1988.03720020027031

  43. 43.

    Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40:795-796.

    Not in our library10.1161/01.hyp.0000038733.08436.98

  44. 44.

    Vinyoles E, Felip A, Pujol E, de la Sierra A, Durà R, del Rey RH, et al. Clinical characteristics of isolated clinic hypertension. J Hypertens. 2008;26:438-445.

    Not in our library10.1097/hjh.0b013e3282f3150b

  45. 45.

    Shin J, Park SH, Kim JH, Ihm SH, Kim KI, Kim WS, et al. Discordance between ambulatory versus clinic blood pressure according to global cardiovascular risk group. Korean J Intern Med. 2015;30:610-619.

    Not in our library10.3904/kjim.2015.30.5.610

  46. 46.

    Hwang ES, Choi KJ, Kang DH, Nam GB, Jang JS, Jeong YH, et al. Prevalence, predictive factor, and clinical significance of white-coat hypertension and masked hypertension in Korean hypertensive patients. Korean J Intern Med. 2007;22:256-262.

    Not in our library10.3904/kjim.2007.22.4.256

  47. 47.

    Verdecchia P, Palatini P, Schillaci G, Mormino P, Porcellati C, Pessina AC. Independent predictors of isolated clinic (‘white-coat’) hypertension. J Hypertens. 2001;19:1015-1020.

    Not in our library10.1097/00004872-200106000-00004

  48. 48.

    Obara T, Ohkubo T, Funahashi J, Kikuya M, Asayama K, Metoki H, et al. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. J Hypertens. 2005;23:1653-1660.

    Not in our library10.1097/01.hjh.0000178334.33352.56

  49. 49.

    Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208.

    Not in our library10.1161/01.hyp.0000151623.49780.89

  50. 50.

    Banegas JR, Ruilope LM, de la Sierra A, de la Cruz JJ, Gorostidi M, Segura J, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J. 2014;35:3304-3312.

    Not in our library10.1093/eurheartj/ehu016

  51. 51.

    Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C. Prognostic significance of the white coat effect. Hypertension. 1997;29:1218-1224.

    Not in our library10.1161/01.hyp.29.6.1218

  52. 52.

    Verberk WJ, Kessels AG, de Leeuw PW. Prevalence, causes, and consequences of masked hypertension: a meta-analysis. Am J Hypertens. 2008;21:969-975.

    Not in our library10.1038/ajh.2008.221

  53. 53.

    Björklund K, Lind L, Zethelius B, Andrén B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation. 2003;107:1297-1302.

    Not in our library10.1161/01.cir.0000054622.45012.12

  54. 54.

    Kim HJ, Shin JH, Lee Y, Kim JH, Hwang SH, Kim WS, et al. Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry. Korean J Intern Med. 2021;36:1102-1114.

    Not in our library10.3904/kjim.2020.650

  55. 55.

    Hänninen MR, Niiranen TJ, Puukka PJ, Mattila AK, Jula AM. Determinants of masked hypertension in the general population: the Finn-home study. J Hypertens. 2011;29:1880-1888.

    Not in our library10.1097/hjh.0b013e32834a98ba

  56. 56.

    Asayama K, Thijs L, Li Y, Gu YM, Hara A, Liu YP, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension. 2014;64:935-942.

    Not in our library10.1161/hypertensionaha.114.03614

  57. 57.

    Viera AJ, Lin FC, Tuttle LA, Olsson E, Stankevitz K, Girdler SS, et al. Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit. 2014;19:208-215.

    Not in our library10.1097/mbp.0000000000000054

  58. 58.

    SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116.

    Not in our library10.1056/nejmoa1511939

  59. 59.

    Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ. 2011;342:d286.

    Not in our library10.1136/bmj.d286

  60. 60.

    Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. The conventional versus automated measurement of blood pressure in the office (CAMBO) trial: masked hypertension sub-study. J Hypertens. 2012;30:1937-1941.

    Not in our library10.1097/hjh.0b013e328356abd3

  61. 61.

    Wohlfahrt P, Cífková R, Movsisyan N, Kunzová Š, Lešovský J, Homolka M, et al. Threshold for diagnosing hypertension by automated office blood pressure using random sample population data. J Hypertens. 2016;34:2180-2186.

    Not in our library10.1097/hjh.0000000000001076

  62. 62.

    Myers MG, Kaczorowski J. Office blood pressure is lower than awake ambulatory blood pressure at lower targets for treatment. J Clin Hypertens (Greenwich). 2017;19:1210-1213.

    Not in our library10.1111/jch.13090

  63. 63.

    Lee HY, Lee DJ, Seo J, Ihm SH, Kim KI, Cho EJ, et al. Smartphone / smartwatch-based cuffless blood pressure measurement: a position paper from the Korean Society of Hypertension. Clin Hypertens. 2021;27:4.

    Not in our library10.1186/s40885-020-00158-8

  64. 64.

    McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35:1719-1725.

    Not in our library10.1093/eurheartj/eht565

  65. 65.

    Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203.

    Not in our library10.1161/hypertensionaha.107.089078

  66. 66.

    Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019;381:243-251.

    Not in our library10.1056/nejmoa1803180

  67. 67.

    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.

    Not in our library10.1016/s0140-6736(02)11911-8

  68. 68.

    US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, et al. Screening for hypertension in adults: US preventive services task force reaffirmation recommendation statement. JAMA. 2021;325:1650-1656.

    Not in our library10.1001/jama.2021.4987

  69. 69.

    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.

    Not in our library10.1001/jama.2013.284427

  70. 70.

    Guirguis-Blake JM, Evans CV, Webber EM, Coppola EL, Perdue LA, Weyrich MS. Screening for hypertension in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2021;325:1657-1669.

    Not in our library10.1001/jama.2020.21669

  71. 71.

    Kaczorowski J, Chambers LW, Dolovich L, Paterson JM, Karwalajtys T, Gierman T, et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of cardiovascular health awareness program (CHAP). BMJ. 2011;342:d442.

    Not in our library10.1136/bmj.d442

  72. 72.

    Mann AH. The psychological effect of a screening programme and clinical trial for hypertension upon the participants. Psychol Med. 1977;7:431-438.

    Not in our library10.1017/s0033291700004402

  73. 73.

    Ameling EH, de Korte DF, Man in 't Veld A. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol. 1991;18:752-760.

    Not in our library10.1097/00005344-199111000-00014

  74. 74.

    Tompson AC, Ward AM, McManus RJ, Perera R, Thompson MJ, Heneghan CJ, et al. Acceptability and psychological impact of out-of-office monitoring to diagnose hypertension: an evaluation of survey data from primary care patients. Br J Gen Pract. 2019;69:e389-e397.

    Not in our library10.3399/bjgp19x702221

  75. 75.

    Verdecchia P, Angeli F, Borgioni C, Gattobigio R, Reboldi G. Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension. 2007;49:777-783.

    Not in our library10.1161/01.hyp.0000258215.26755.20

  76. 76.

    Viera AJ, Lingley K, Hinderliter AL. Tolerability of the Oscar 2 ambulatory blood pressure monitor among research participants: a cross-sectional repeated measures study. BMC Med Res Methodol. 2011;11:59.

    Not in our library10.1186/1471-2288-11-59

  77. 77.

    Sherwood A, Hill LK, Blumenthal JA, Hinderliter AL. The effects of ambulatory blood pressure monitoring on sleep quality in men and women with hypertension: dipper vs. nondipper and race differences. Am J Hypertens. 2019;32:54-60.

    Not in our library10.1093/ajh/hpy138

  78. 78.

    Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337.

    Not in our library10.1093/eurheartj/ehab484

  79. 79.

    Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483.

    Not in our library10.1056/nejmra054415

  80. 80.

    Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221-226.

    Not in our library10.1053/ajkd.2002.34487

  81. 81.

    Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29.

    Not in our library10.1056/nejmoa1114248

  82. 82.

    Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD epidemiology collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis. 2013;61:57-66.

    Not in our library10.1053/j.ajkd.2012.06.016

  83. 83.

    2013 KDIGO. Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011). 2013;3:19–62.

    Not in our library10.1038/kisup.2012.64

  84. 84.

    Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012;197:224-225.

    Not in our library10.5694/mja11.11468

  85. 85.

    Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923-934.

    Not in our library10.1097/hjh.0b013e32832aa6b5

  86. 86.

    Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184-191.

    Not in our library10.7326/m14-0773

  87. 87.

    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

    Not in our library10.1136/bmj.b1665

  88. 88.

    Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-2020.

    Not in our library10.1056/nejmoa1600175

  89. 89.

    Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-443.

    Not in our library10.1016/s0140-6736(15)00805-3

  90. 90.

    Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels: updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613-622.

    Not in our library10.1097/hjh.0000000000000881

  91. 91.

    Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, et al. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157-2172.

    Not in our library10.1097/01.hjh.0000194120.42722.ac

  92. 92.

    Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500-1508.

    Not in our library10.1093/eurheartj/ehr039

  93. 93.

    Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.

    Not in our library10.1016/s0140-6736(09)60503-1

  94. 94.

    Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140:e596-e646.

    Not in our library10.1161/cir.0000000000000678

  95. 95.

    US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, et al. Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement. JAMA. 2022;327:1577-1584.

    Not in our library10.1001/jama.2022.4983

  96. 96.

    Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104.

    Not in our library10.1093/eurheartj/ehy339

  97. 97.

    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.

    Not in our library10.1056/nejmoa0807646

  98. 98.

    Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-2031.

    Not in our library10.1056/nejmoa1600176

  99. 99.

    Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.

    Not in our library10.1016/s0140-6736(10)61350-5

  100. 100.

    Hur KY, Moon MK, Park JS, Kim SK, Lee SH, Yun JS, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021;45:461-481.

    Not in our library10.4093/dmj.2021.0156

  101. 101.

    Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2018;139:2089-2097.

    Not in our library10.1161/circulationaha.118.037076

  102. 102.

    Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJ, Agarwal R, et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021;143:1735-1749.

    Not in our library10.1161/circulationaha.120.048740

  103. 103.

    Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171:1173-1180.

    Not in our library10.1001/archinternmed.2011.276

  104. 104.

    Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46-56.

    Not in our library10.1001/jama.2013.6549

  105. 105.

    Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-546.

    Not in our library10.1177/1740774514537404

  106. 106.

    Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158.

    Not in our library10.1136/bmj.h158

  107. 107.

    Birtwhistle RV, Godwin MS, Delva MD, Casson RI, Lam M, MacDonald SE, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ. 2004;328:204.

    Not in our library10.1136/bmj.37967.374063.ee

  108. 108.

    Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24:302-316.

    Not in our library10.1016/s0149-2918(02)85026-3

  109. 109.

    Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722-732.

    Not in our library10.1001/archinte.164.7.722

  110. 110.

    Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.

    Not in our library10.1016/j.amjmed.2006.08.033

  111. 111.

    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.

    Not in our library10.1161/hypertensionaha.109.139816

  112. 112.

    Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394:672-683.

    Not in our library10.1016/s0140-6736(19)31791-x

  113. 113.

    Tung YC, Huang YC, Wu LS, Chang CJ, Chu PH. Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment. J Clin Hypertens (Greenwich). 2017;19:983-989.

    Not in our library10.1111/jch.13035

  114. 114.

    Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177.

    Not in our library10.1093/eurheartj/ehx393

  115. 115.

    ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.

    Not in our library10.1056/nejmoa1001286

  116. 116.

    Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.

    Not in our library10.1016/s0140-6736(07)61303-8

  117. 117.

    Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603-615.

    Not in our library10.1001/jama.2014.18574

  118. 118.

    Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717.

    Not in our library10.1136/bmj.i717

  119. 119.

    Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268-1279.

    Not in our library10.1056/nejmoa2111437

  120. 120.

    Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care. 2017;40:1733-1738.

    Not in our library10.2337/dc17-1366

  121. 121.

    Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.

    Not in our library10.1016/s0140-6736(03)14739-3

  122. 122.

    Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.

    Not in our library10.1016/s0140-6736(02)08090-x

  123. 123.

    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542-549.

    Not in our library10.7326/0003-4819-138-7-200304010-00010

  124. 124.

    Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047-2056.

    Not in our library10.1016/s0140-6736(14)62459-4

  125. 125.

    Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211-220.

    Not in our library10.1016/s2213-8587(15)00417-9

  126. 126.

    Juraschek SP, Hu JR, Cluett JL, Ishak A, Mita C, Lipsitz LA, et al. Effects of intensive blood pressure treatment on orthostatic hypotension: a systematic review and individual participant-based meta-analysis. Ann Intern Med. 2021;174:58-68.

    Not in our library10.7326/m20-4298

  127. 127.

    Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1294-1309.

    Not in our library10.1016/j.jacc.2018.05.079

  128. 128.

    Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775-781.

    Not in our library10.1001/jamacardio.2017.1421

  129. 129.

    Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374-384.

    Not in our library10.1161/01.hyp.0000231662.77359.de

  130. 130.

    Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163-2168.

    Not in our library10.1097/01.hjh.0000249692.96488.46

  131. 131.

    Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JF, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226-2237.

    Not in our library10.1016/s0140-6736(17)30754-7

  132. 132.

    Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-Term Evaluation. Am J Hypertens. 1999;12:665-672.

    Not in our library10.1016/s0895-7061(99)00042-4

  133. 133.

    Fox KM. EURopean trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.

    Not in our library10.1016/s0140-6736(03)14286-9

  134. 134.

    Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.

    Not in our library10.1016/j.jacc.2004.11.070

  135. 135.

    Zhao D, Wang ZM, Wang LS. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29:475-485.

    Not in our library10.7555/jbr.29.20140149

  136. 136.

    Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kääb S, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost. 2011;106:1012-1019.

    Not in our library10.1160/th11-07-0517

  137. 137.

    Lee KH, Kim JB, Shin SY, Joung B. 2021 Korean Heart Rhythm Society guidelines for stroke prevention in atrial fibrillation. Korean J Med. 2021;96:296-311.

    Not in our library10.3904/kjm.2021.96.4.296

  138. 138.

    Nakamura K, Stefanescu SA. Treatment of hypertension in coarctation of the aorta. Curr Treat Options Cardiovasc Med. 2016;18:40.

    Not in our library10.1007/s11936-016-0462-x

  139. 139.

    Schaefer BM, Lewin MB, Stout KK, Gill E, Prueitt A, Byers PH, et al. The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. Heart. 2008;94:1634-1638.

    Not in our library10.1136/hrt.2007.132092

  140. 140.

    Davies RR, Kaple RK, Mandapati D, Gallo A, Botta DM, Elefteriades JA, et al. Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg. 2007;83:1338-1344.

    Not in our library10.1016/j.athoracsur.2006.10.074

  141. 141.

    Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. Circulation. 2013;128:1281-1283.

    Not in our library10.1161/circulationaha.113.005275

  142. 142.

    Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-548.

    Not in our library10.7326/0003-4819-154-8-201104190-00335

  143. 143.

    Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009;3:CD004349.

    Not in our library10.1002/14651858.cd004349.pub2

  144. 144.

    Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.

    Not in our library10.1097/01.hjh.0000431740.32696.cc

  145. 145.

    Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918-929.

    Not in our library10.1056/nejmoa0910975

  146. 146.

    Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903.

    Not in our library10.1056/nejmoa1303154

  147. 147.

    Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728-741.

    Not in our library10.1053/j.ajkd.2015.10.011

  148. 148.

    Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-87.

    Not in our library10.1016/j.kint.2020.11.003

  149. 149.

    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.

    Not in our library10.1056/nejmoa1208799

  150. 150.

    Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812-2823.

    Not in our library10.1681/asn.2017020148

  151. 151.

    Tomson CR, Cheung AK, Mann JF, Chang TI, Cushman WC, Furth SL, et al. Management of blood pressure in patients with chronic kidney disease not receiving dialysis: synopsis of the 2021 KDIGO clinical practice guideline. Ann Intern Med. 2021;174:1270-1281.

    Not in our library10.7326/m21-0834

  152. 152.

    National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.

    Not in our library10.1056/nejm199512143332401

  153. 153.

    Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.

    Not in our library10.1056/nejmoa0804656

  154. 154.

    Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20.

    Not in our library10.1056/nejmoa1411587

  155. 155.

    Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030.

    Not in our library10.1056/nejmoa1414905

  156. 156.

    Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285-2295.

    Not in our library10.1056/nejmoa1415061

  157. 157.

    Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-1018.

    Not in our library10.1056/nejmoa1414792

  158. 158.

    Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296-2306.

    Not in our library10.1056/nejmoa1503780

  159. 159.

    Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016;15:1138-1147.

    Not in our library10.1016/s1474-4422(16)30177-6

  160. 160.

    Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11-21.

    Not in our library10.1056/nejmoa1706442

  161. 161.

    Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708-718.

    Not in our library10.1056/nejmoa1713973

  162. 162.

    Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, et al. Effects of antihypertensive treatment after acute stroke in the continue or stop post-stroke antihypertensives collaborative study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010;9:767-775.

    Not in our library10.1016/s1474-4422(10)70163-0

  163. 163.

    He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311:479-489.

    Not in our library10.1001/jama.2013.282543

  164. 164.

    Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377:741-750.

    Not in our library10.1016/s0140-6736(11)60104-9

  165. 165.

    Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-2365.

    Not in our library10.1056/nejmoa1214609

  166. 166.

    Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-1043.

    Not in our library10.1056/nejmoa1603460

  167. 167.

    Rodriguez-Luna D, Piñeiro S, Rubiera M, Ribo M, Coscojuela P, Pagola J, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277-1283.

    Not in our library10.1111/ene.12180

  168. 168.

    Sakamoto Y, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke. 2013;44:1846-1851.

    Not in our library10.1161/strokeaha.113.001212

  169. 169.

    Tsivgoulis G, Katsanos AH, Butcher KS, Boviatsis E, Triantafyllou N, Rizos I, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83:1523-1529.

    Not in our library10.1212/wnl.0000000000000917

  170. 170.

    Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA, Wang J. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032-1040.

    Not in our library10.1038/hr.2009.139

  171. 171.

    Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med. 2009;2:30.

    Not in our library10.1186/1755-7682-2-30

  172. 172.

    Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G, et al. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke. 2012;43:1675-1677.

    Not in our library10.1161/strokeaha.112.651448

  173. 173.

    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.

    Not in our library10.1016/s0140-6736(01)06178-5

  174. 174.

    Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967.

    Not in our library10.1016/s0140-6736(15)01225-8

  175. 175.

    SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-515.

    Not in our library10.1016/s0140-6736(13)60852-1

  176. 176.

    La Torre A, Giupponi G, Duffy D, Conca A, Catanzariti D. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry. 2015;48:1-6.

    Not in our library10.1055/s-0034-1395515

  177. 177.

    Foy CG, Newman JC, Berlowitz DR, Russell LP, Kimmel PL, Wadley VG, et al. Blood pressure, sexual activity, and dysfunction in women with hypertension: baseline findings from the Systolic Blood Pressure Intervention Trial (SPRINT). J Sex Med. 2016;13:1333-1346.

    Not in our library10.1016/j.jsxm.2016.06.014

  178. 178.

    National Institute for Health and Clinical Excellence (NICE). Hypertension in adults: diagnosis and management. 2011.

    Not in our library

  179. 179.

    Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683-689.

    Not in our library10.1016/s1474-4422(08)70143-1

  180. 180.

    Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-2160.

    Not in our library10.1001/archinte.1994.00420190047006

  181. 181.

    Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.

    Not in our library10.1016/s0140-6736(98)03086-4

  182. 182.

    Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.

    Not in our library10.1001/archinte.162.18.2046

  183. 183.

    Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.

    Not in our library10.1001/archinte.163.9.1069

  184. 184.

    Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.

    Not in our library10.1097/00004872-200305000-00011

  185. 185.

    Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020;323:1934-1944.

    Not in our library10.1001/jama.2020.4249

  186. 186.

    SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553-561.

    Not in our library10.1001/jama.2018.21442

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.